Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adaptive BiotechnologiesADPT -0.20%65 3-Year EBITDA Growth Rate is 45.70% as of Jun. 2026. GuruFocus rates ADPT with a GF Score™ of 65/100 and a GF Value™ of $11.76 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 164 Medical Diagnostics & Research companies, Adaptive Biotechnologies ranks better than 81.71% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 45.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 24.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Adaptive Biotechnologies was 45.70% per year. The lowest was -49.40% per year. And the median was -6.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Adaptive Biotechnologies 3-Year EBITDA Growth Rate Related Terms
ADPT vs GRAL, VCYT, RDNT: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Adaptive Biotechnologies's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adaptive Biotechnologies 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Adaptive Biotechnologies's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Adaptive Biotechnologies's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 45.70% mean?
Adaptive Biotechnologies (ADPT) has a 3-Year EBITDA Growth Rate of 45.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Adaptive Biotechnologies and its competitors. According to the industry distribution chart, Adaptive Biotechnologies ranks #30 out of 164 companies in the Medical Diagnostics & Research industry, placing it in the top 18.3%.
Is Adaptive Biotechnologies' 3-Year EBITDA Growth Rate too high?
Adaptive Biotechnologies' current 3-Year EBITDA Growth Rate is 45.70%. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 11.05. Adaptive Biotechnologies' value of 45.70% is 313.6% above this industry median. Based on the distribution chart, Adaptive Biotechnologies ranks #30 out of 164 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Adaptive Biotechnologies has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adaptive Biotechnologies' 3-Year EBITDA Growth Rate compare to GRAL and VCYT?
According to the Medical Diagnostics & Research industry distribution chart, Adaptive Biotechnologies ranks #30 out of 164 companies for 3-Year EBITDA Growth Rate. This places Adaptive Biotechnologies in the top 18% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 11.05. Adaptive Biotechnologies' value of 45.70% is 313.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.05, based on 164 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adaptive Biotechnologies's current 3-Year EBITDA Growth Rate of 45.70% is 313.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Adaptive Biotechnologies and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adaptive Biotechnologies's current 3-Year EBITDA Growth Rate is 45.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptive Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Adaptive Biotechnologies (ADPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $11.76, compared to a current price of $25.44 — trading 116.3% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 45.70% and 313.6% above the Medical Diagnostics & Research industry median of 11.05. Adaptive Biotechnologies' overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Adaptive Biotechnologies (ADPT), the current 3-Year EBITDA Growth Rate is 45.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adaptive Biotechnologies (ADPT) Overvalued in 2026?
Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued.
The current stock price of $25.44 is trading 116.3% above its estimated GF Value™ of $11.76.
GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.
Key valuation signals for ADPT:
3-Year EBITDA Growth Rate: 45.70%
GF Value™: $11.76 vs. price of $25.44 (116.3% above fair value)
Industry Position: 313.6% above the Medical Diagnostics & Research median (#30 of 164)
No single metric tells the full story. See the ADPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
65GF Score
Get the complete analysis for ADPT
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADPT has been successfully added to your 
